Drug Trial Radar · NCT07893093
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Sep 28, 2026
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Ascletis Pharma (China) Co., LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Two Formulations of ASC36 injection
Conditions
- Chronic Weight Management
Interventions
ASC36 Injection A, for subcutaneous useDrug
ASC36 Injection A is an investigational formulation of ASC36 administered by subcutaneous injection.
ASC36 Placebo Injection A, for subcutaneous useDrug
ASC36 Placebo Injection A is an placebo injection matching ASC36 Injection A.
ASC36 Injection B, for subcutaneous useDrug
ASC36 Injection B is an investigational formulation of ASC36 administered by subcutaneous injection.
ASC36 Placebo Injection B, for subcutaneous useDrug
ASC36 Placebo Injection B is an placebo injection matching ASC36 Injection B.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: From baseline to the end of treatment (up to 16 weeks or Day 113)
- Adverse EventsTime frame: From baseline to the end of treatment (up to 20 weeks or Day 141)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Ascletis Clinical Site
San Antonio, Texas · Recruiting
Ascletis Clinical Site
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.